| scholarly article | Q13442814 |
| P356 | DOI | 10.4149/NEO_2011_06_482 |
| P698 | PubMed publication ID | 21895401 |
| P2093 | author name string | Q Li | |
| H Hu | |||
| H Gu | |||
| Y Han | |||
| C Gu | |||
| N Wu | |||
| P2860 | cites work | The blooming of the French lilac | Q22241897 |
| P433 | issue | 6 | |
| P921 | main subject | apoptotic process | Q14599311 |
| metformin | Q19484 | ||
| lung cancer | Q47912 | ||
| P304 | page(s) | 482-490 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Neoplasma | Q15761100 |
| P1476 | title | Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153 | |
| P478 | volume | 58 |
| Q36681789 | (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-κB and up-regulation of TNFRSF10B (DR5). |
| Q35200421 | Association of the metformin with the risk of lung cancer: a meta-analysis |
| Q37149246 | Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. |
| Q37640678 | Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice |
| Q92912028 | CHTM1 regulates cancer cell sensitivity to metabolic stress via p38-AIF1 pathway |
| Q38033044 | Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. |
| Q89736197 | Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes |
| Q36402823 | Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony |
| Q33748862 | Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis |
| Q89422561 | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| Q38954598 | Differential effects of AMPK agonists on cell growth and metabolism |
| Q90662131 | Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells |
| Q35603449 | Effect of Metformin on Viability, Morphology, and Ultrastructure of Mouse Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells and Balb/3T3 Embryonic Fibroblast Cell Line |
| Q46882768 | Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients |
| Q33551333 | Effect of metformin on prostate cancer outcomes after radical prostatectomy |
| Q98771721 | Hepatic Stellate Cells and Hepatocarcinogenesis |
| Q33594115 | Hyperglycemia, a neglected factor during cancer progression |
| Q49233912 | Identification of human age-associated gene co-expressions in functional modules using liquid association |
| Q47128274 | Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells |
| Q38289532 | Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics |
| Q38789150 | Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK. |
| Q55240881 | Metformin and Autoimmunity: A "New Deal" of an Old Drug. |
| Q36423076 | Metformin and its clinical use: new insights for an old drug in clinical practice. |
| Q90627670 | Metformin attenuates cadmium-induced neuronal apoptosis in vitro via blocking ROS-dependent PP5/AMPK-JNK signaling pathway |
| Q34957038 | Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma |
| Q34104019 | Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. |
| Q38674016 | Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro. |
| Q37609790 | Metformin targets multiple signaling pathways in cancer |
| Q38734576 | Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system |
| Q36334079 | Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway |
| Q35145204 | Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma |
| Q37301923 | Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma |
| Q36725003 | Reversing the Warburg effect as a treatment for glioblastoma |
| Q93148944 | Role of p53 Family Proteins in Metformin Anti-Cancer Activities |
| Q48252582 | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
| Q35153493 | Survival of patients with stage IV lung cancer with diabetes treated with metformin |
| Q37011502 | Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy |
| Q39146805 | The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway |
| Q33912895 | The effect of 5-aminoimidazole-4-carboxamide-ribonucleoside was mediated by p38 mitogen activated protein kinase signaling pathway in FRO thyroid cancer cells |
| Q90214862 | p-21 Activated Kinase as a Molecular Target for Chemoprevention in Diabetes |
Search more.